Tempest Therapeutics, Inc. Common Stock TPST
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $7.00 (+1727.7% upside)
Key Stats
- Today's Range
- $0.37 – $0.40
- 50-Day Range
- $0.34 – $1.48
- 52-Week Range
- $0.34 – $12.23
- Volume
- 132K shs
- Average Volume
- 279K shs
- Market Cap
- $7.66 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.88%
- Days to Cover
- 1.00
About Tempest Therapeutics, Inc. Common Stock
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Related Stocks
Compare head-to-head: TPST vs LLY·TPST vs JNJ·TPST vs ABBV·TPST vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.